Barclays’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-164,104
| Closed | -$3.19M | – | 7601 |
|
|
2018
Q1 | $3.19M | Buy |
164,104
+49,748
| +44% | +$976K | ﹤0.01% | 2002 |
|
|
2017
Q4 | $1.91M | Buy |
114,356
+32,355
| +39% | +$593K | ﹤0.01% | 2477 |
|
|
2017
Q3 | $1.67M | Sell |
82,001
-5,979
| -7% | -$114K | ﹤0.01% | 2525 |
|
|
2017
Q2 | $1.42M | Buy |
87,980
+86,428
| +5,569% | +$1.28M | ﹤0.01% | 2569 |
|
|
2017
Q1 | $19K | Sell |
1,552
-10,047
| -87% | -$121K | ﹤0.01% | 5839 |
|
|
2016
Q4 | $154K | Buy |
11,599
+10,287
| +784% | +$176K | ﹤0.01% | 4424 |
|
|
2016
Q3 | $31K | Sell |
1,312
-99,335
| -99% | -$2.67M | ﹤0.01% | 5262 |
|
|
2016
Q2 | $2.9M | Buy |
100,647
+100,199
| +22,366% | +$3.27M | ﹤0.01% | 1718 |
|
|
2016
Q1 | $14K | Sell |
448
-23,491
| -98% | -$826K | ﹤0.01% | 5378 |
|
|
2015
Q4 | $1.01M | Sell |
23,939
-17,154
| -42% | -$685K | ﹤0.01% | 2609 |
|
|
2015
Q3 | $1.44M | Buy |
41,093
+37,369
| +1,003% | +$1.68M | ﹤0.01% | 2405 |
|
|
2015
Q2 | $168K | Sell |
3,724
-6,351
| -63% | -$301K | ﹤0.01% | 4271 |
|
|
2015
Q1 | $463K | Sell |
10,075
-107,257
| -91% | -$4.27M | ﹤0.01% | 3678 |
|
|
2014
Q4 | $3.64M | Buy |
117,332
+59,512
| +103% | +$1.74M | ﹤0.01% | 1975 |
|
|
2014
Q3 | $1.33M | Buy |
57,820
+33,334
| +136% | +$854K | ﹤0.01% | 3049 |
|
|
2014
Q2 | $710K | Buy |
24,486
+10,026
| +69% | +$270K | ﹤0.01% | 3653 |
|
|
2014
Q1 | $376K | Buy |
14,460
+1,844
| +15% | +$46.1K | ﹤0.01% | 4184 |
|
|
2013
Q4 | $316K | Sell |
12,616
-25,099
| -67% | -$560K | ﹤0.01% | 4546 |
|
|
2013
Q3 | $755K | Sell |
37,715
-12,511
| -25% | -$258K | ﹤0.01% | 3660 |
|
|
2013
Q2 | $1M | Buy |
+50,226
| New | +$892K | ﹤0.01% | 3354 |
|
Barclays's IPXL Position: Q2 2018 in Review
Barclays sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 164,104 shares — an estimated $3.19M sold.
Barclays first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $3.64M in Q4 2014. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Barclays reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Barclays sold 164,104 Impax Laboratories, Inc. shares in Q2 2018, an estimated $3.19M.
- Barclays first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- Barclays's Impax Laboratories, Inc. position peaked at $3.64M in Q4 2014.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.